||5R01CA204378-02 Interpret this number
||Fred Hutchinson Cancer Research Center
||Improving Treatment of Cardiovascular Risk Factors in Childhood Cancer Survivors
Children and adolescents diagnosed with cancer now have on average >80% 5-year survival. However,
premature cardiovascular (CV) disease has become the leading non-cancer cause of late mortality among
childhood cancer survivors. Our existing work has shown that traditional CV risk factors such as hypertension,
dyslipidemia, insulin resistance/diabetes remain very important, by increasing (in synergistic fashion) the risk of
major CV events such as ischemic heart disease and heart failure. However, the existing research has been
limited by misclassification of CV risk factor status (i.e., when defined by self-report or medication usage
alone), including issues with both underdiagnosis (i.e., people with these risk factors present but who are
unaware) and uncertainty of disease control (i.e., potential undertreatment). This proposal will utilize the
largest, best characterized childhood cancer survivor cohort in the world, the Childhood Cancer Survivor Study
(CCSS; n=24,466), a NCI-funded resource. We will use CCSS-derived validated risk prediction algorithms to
select survivors at high risk of serious heart disease (n=800) based on past cancer treatment exposures.
Among these 800 survivors, we propose to determine the magnitude of underdiagnosis and undertreatment of
hypertension, dyslipidemia, and diabetes via in-person (home-based) measurements supplemented by medical
record review. We predict that around 60% of survivors (n~480) will be underdiagnosed or undertreated with
respect to one of these three CV risk factors. Survivors who are underdiagnosed or undertreated will then be
eligible to participate in a 1-year long randomized controlled trial, where we will measure the efficacy of an
Institute of Medicine (IOM) recommended personalized survivorship care plan (SCP) emphasizing CV risk,
supplemented by a remotely delivered clinician-led self-management counseling intervention, to improve
control of these three CV risk factors (i.e., reduce rates of undertreated hypertension, dyslipidemia, and
diabetes). Survivors randomized to the control arm can receive the intervention on a delayed basis. Finally, our
proposal seeks to better understand barriers among survivors and their primary healthcare providers that
contribute to CV risk factor undertreatment. Knowledge derived from this study will improve the assessment
and treatment of important CV risk factors in this high risk population. The proposed intervention, if successful,
will be disseminable and low cost, and will have the potential to improve health and reduce mortality in these
younger adults who live the majority of their lives as cancer survivors at increased risk of serious CV disease.
Lasting effects of cancer and its treatment on employment and finances in adolescent and young adult cancer survivors.
, Syrjala K.L.
, Casillas J.
, Jacobs L.A.
, Palmer S.C.
, McCabe M.S.
, Ganz P.A.
, Overholser L.
, Partridge A.
, Rajotte E.J.
, et al.
Cancer, 2019-06-01; 125(11), p. 1908-1917.
Long-term complications in adolescent and young adult leukemia survivors.
, Syrjala K.L.
Hematology. American Society of Hematology. Education Program, 2018-11-30; 2018(1), p. 146-153.
Prediction of cardiovascular disease among hematopoietic cell transplantation survivors.
, Yang D.
, Teh J.B.
, Atencio L.C.
, Gonzales A.
, Wong F.L.
, Leisenring W.M.
, Forman S.J.
, Nakamura R.
, Chow E.J.
Blood advances, 2018-07-24; 2(14), p. 1756-1764.
New Agents, Emerging Late Effects, and the Development of Precision Survivorship.
, Antal Z.
, Constine L.S.
, Gardner R.
, Wallace W.H.
, Weil B.R.
, Yeh J.M.
, Fox E.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-20; 36(21), p. 2231-2240.
Prediction of Ischemic Heart Disease and Stroke in Survivors of Childhood Cancer.
, Chen Y.
, Hudson M.M.
, Feijen E.A.M.
, Kremer L.C.
, Border W.L.
, Green D.M.
, Meacham L.R.
, Mulrooney D.A.
, Ness K.K.
, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-01-01; 36(1), p. 44-52.